Malignant fibrous histiocytoma epidemiology and demographics: Difference between revisions
Nawal Muazam (talk | contribs) No edit summary |
Nawal Muazam (talk | contribs) No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}};{{AE}} {{NM}} | {{CMG}};{{AE}} {{NM}} | ||
==Overview== | ==Overview== | ||
Males are more commonly affected with myelodysplastic syndrome than females. The male to female ratio is 1.2:1. | |||
==Epidemiology and Demographics== | ==Epidemiology and Demographics== | ||
===Prevalence=== | ===Prevalence=== | ||
===Incidence=== | ===Incidence=== | ||
===Age=== | ===Age=== | ||
Myelodysplastic syndrome commonly affects individuals between 32-80 (mean 59 years) years of age. | |||
===Gender=== | ===Gender=== | ||
===Race=== | ===Race=== | ||
Revision as of 18:05, 17 December 2015
|
Malignant fibrous histiocytoma Microchapters |
|
Differentiating Malignant Fibrous Histiocytoma from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Malignant fibrous histiocytoma epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Malignant fibrous histiocytoma epidemiology and demographics |
|
FDA on Malignant fibrous histiocytoma epidemiology and demographics |
|
CDC on Malignant fibrous histiocytoma epidemiology and demographics |
|
Malignant fibrous histiocytoma epidemiology and demographics in the news |
|
Blogs on Malignant fibrous histiocytoma epidemiology and demographics |
|
Directions to Hospitals Treating Malignant fibrous histiocytoma |
|
Risk calculators and risk factors for Malignant fibrous histiocytoma epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Nawal Muazam M.D.[2]
Overview
Males are more commonly affected with myelodysplastic syndrome than females. The male to female ratio is 1.2:1.
Epidemiology and Demographics
Prevalence
Incidence
Age
Myelodysplastic syndrome commonly affects individuals between 32-80 (mean 59 years) years of age.